# OnCo record idea-upgrade-neratinib-two-week-dose-escalation-by-default (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-upgrade-neratinib-two-week-dose-escalation-by-default/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-upgrade-neratinib-two-week-dose-escalation-by-default" ;
  schema:name "Start neratinib at a lower dose and build up over two weeks, as the default"@en ;
  schema:description "Neratinib, a tablet for HER2-positive breast cancer, gives almost everyone diarrhoea, and many stop it early because of that. Starting at half the dose and building up over two weeks gave the least severe diarrhoea of any strategy tested, and the US label now allows it. The evidence comes from cohorts that were not randomised against each other, so a direct comparison is still owed."@en ;
  schema:url <https://onco.cc/ideas/idea-upgrade-neratinib-two-week-dose-escalation-by-default/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.breast.2022.12.003>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1e41dcf-e82a-47c2-a0ad-6c6eef621834> ;
  onco:tag "protocol-upgrade", "upgrade:promising", "evidence:moderate" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/her2-tyrosine-kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/neratinib/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/> .